Vaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 38.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 408,274 shares of the company's stock after purchasing an additional 112,512 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.33% of Vaxcyte worth $46,653,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of PCVX. Blue Trust Inc. raised its holdings in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock worth $42,000 after purchasing an additional 93 shares during the last quarter. Nisa Investment Advisors LLC grew its position in Vaxcyte by 5.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the company's stock worth $252,000 after purchasing an additional 110 shares during the period. CIBC Asset Management Inc raised its stake in shares of Vaxcyte by 3.6% during the 3rd quarter. CIBC Asset Management Inc now owns 3,136 shares of the company's stock valued at $358,000 after buying an additional 110 shares during the last quarter. Amalgamated Bank lifted its holdings in shares of Vaxcyte by 4.2% in the 2nd quarter. Amalgamated Bank now owns 3,759 shares of the company's stock valued at $284,000 after buying an additional 150 shares during the period. Finally, Riverview Trust Co purchased a new stake in shares of Vaxcyte in the third quarter worth about $27,000. Institutional investors and hedge funds own 96.78% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on PCVX. Jefferies Financial Group lifted their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Needham & Company LLC restated a "buy" rating and issued a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, November 6th. Mizuho increased their target price on Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research report on Tuesday, September 10th. Leerink Partners lifted their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the company an "outperform" rating in a research note on Tuesday, September 3rd. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $147.50.

Insider Activity

In other news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total transaction of $927,520.00. Following the sale, the chief financial officer now owns 90,383 shares of the company's stock, valued at approximately $10,479,005.02. This represents a 8.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Grant Pickering sold 7,098 shares of Vaxcyte stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $109.21, for a total transaction of $775,172.58. Following the completion of the transaction, the chief executive officer now owns 138,581 shares of the company's stock, valued at $15,134,431.01. This trade represents a 4.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 110,464 shares of company stock valued at $11,924,596 in the last quarter. Insiders own 3.10% of the company's stock.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX traded up $2.79 during trading on Wednesday, hitting $93.16. 402,091 shares of the company were exchanged, compared to its average volume of 904,458. The company has a fifty day moving average price of $104.69 and a 200-day moving average price of $90.71. The firm has a market capitalization of $11.61 billion, a PE ratio of -19.65 and a beta of 0.94. Vaxcyte, Inc. has a 12-month low of $53.26 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the business earned ($0.91) earnings per share. Research analysts anticipate that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.